Clinical trial
Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline…
NCT00386087 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00386087 |
|---|---|
| Title | Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy |
| Official title | A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Enzastaurin Hydrochloride |
| Enrollment | 41 |
| Start date | Nov 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Oct 11, 2006 |
| Last update posted | Jun 6, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: